Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Gross Margin (2020 - 2025)

Xeris Biopharma Holdings' Gross Margin history spans 6 years, with the latest figure at 87.24% for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin rose 301.0% year-over-year to 87.24%, compared with a TTM value of 85.41% through Dec 2025, up 355.0%, and an annual FY2025 reading of 85.41%, up 355.0% over the prior year.
  • Gross Margin for Q4 2025 was 87.24% at Xeris Biopharma Holdings, up from 85.22% in the prior quarter.
  • The five-year high for Gross Margin was 87.24% in Q4 2025, with the low at 62.01% in Q2 2021.
  • Average Gross Margin over 5 years is 80.17%, with a median of 82.63% recorded in 2022.
  • Year-over-year, Gross Margin skyrocketed 2363bps in 2021 and then plummeted -808bps in 2024.
  • Tracing XERS's Gross Margin over 5 years: stood at 77.19% in 2021, then rose by 5bps to 81.02% in 2022, then grew by 2bps to 82.95% in 2023, then rose by 2bps to 84.23% in 2024, then increased by 4bps to 87.24% in 2025.
  • Per Business Quant, the three most recent readings for XERS's Gross Margin are 87.24% (Q4 2025), 85.22% (Q3 2025), and 83.37% (Q2 2025).